Rimegepant is named as an intervention in 12 current clinical trials in our USA, China, India and UK registers. 5 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Pfizer (7). The most-studied condition is Migraine.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
1 single-substance product containing Rimegepant on the HPRA medicines list.
No entry for Rimegepant in the EMA, FDA or German BfArM shortage lists we track.
| Lead sponsor | Trials |
|---|---|
| Pfizer | 7 |
| Chinese PLA General Hospital | 1 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 1 |
| Ruijin Hospital | 1 |
| Fudan University | 1 |
| Shanghai Zhongshan Hospital | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 7 | 5 |
| Clinical trials in China | 7 | 1 |
| Clinical trials in India | 2 | 1 |
| Clinical trials in UK | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
12 current trials in our USA, China, India and UK registers name Rimegepant (also registered as PF-07899801) as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 5 of the 12 trials are recruiting: 5 with sites in USA, 1 with sites in China, 1 with sites in India and 1 with sites in UK. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Pfizer (7), Chinese PLA General Hospital (1), Second Affiliated Hospital, Zhejiang University, School of Medicine (1) and Ruijin Hospital (1), among 6 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 1 single-substance product containing Rimegepant, for example Vydura 75 mg oral lyophilisate (Pfizer Europe MA EEIG). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Not in the lists we track: Rimegepant has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Rimegepant works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Rimegepant works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Rimegepant (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.